| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
in Response to Bacillus Calmette-Guérin1
*
Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02215;
Genetics Institute, Inc., Cambridge, MA 02140; and
Division Hematology and Oncology, Arthur G. James Cancer Hospital, Columbus, OH 43210
Although Mycobacterium bovis bacillus
Calmette-Guérin (BCG) has been accepted as the most effective
agent in clinical use against superficial bladder cancer, its mechanism
of action remains incompletely understood. A kinetic analysis in
assessing the potential role of cytokines from BCG-stimulated murine
splenocytes showed that IL-12 expression preceded that of other
cytokines. Experiments subtracting endogenous BCG-driven IL-12 using
neutralizing Ab or augmenting its activity with supplemental rIL-12
revealed not only that IL-12 plays a dominant role in IFN-
induction
but also that it is normally dose limiting. A striking increase in
IFN- production could be generated in both mouse and human
immunocompetent cell culture by the addition of even a small amount of
rIL-12. Moreover, this same synergistic effect could be replicated
during in vivo administration of BCG plus rIL-12 into the mouse bladder
and was observed in a patient receiving intravesical combination
therapy. In costimulation cultures, this synergy appeared to partially
rely on IL-18 and IL-2 and could be down-regulated by IL-10. This
suggests that a dynamic interplay between Th1 and Th2 cytokines is
responsible for net IFN- production. The ability of supplemental
exogenous IL-12 to strongly shift this balance toward Th1 provides an
immunological basis for using it in conjunction with intravesical BCG
for bladder cancer immunotherapy.
This article has been cited by other articles:
|
|
 |
|
  D. A. Zaharoff, B. S. Hoffman, H. B. Hooper, C. J. Benjamin Jr., K. K. Khurana, K. W. Hance, C. J. Rogers, P. A. Pinto, J. Schlom, and J. W. Greiner Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12 Cancer Res., August 1, 2009; 69(15): 6192 - 6199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Rothfuchs, J. G. Egen, C. G. Feng, L. R. V. Antonelli, A. Bafica, N. Winter, R. M. Locksley, and A. Sher In Situ IL-12/23p40 Production during Mycobacterial Infection Is Sustained by CD11bhigh Dendritic Cells Localized in Tissue Sites Distinct from Those Harboring Bacilli J. Immunol., June 1, 2009; 182(11): 6915 - 6925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marcenaro, B. Ferranti, M. Falco, L. Moretta, and A. Moretta Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC Int. Immunol., September 1, 2008; 20(9): 1155 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Mitchell, A. M. Hansen, L. Hee, H. J. Ball, S. M. Potter, J. C. Walker, and N. H. Hunt Early Cytokine Production Is Associated with Protection from Murine Cerebral Malaria Infect. Immun., September 1, 2005; 73(9): 5645 - 5653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ashino, T. Oguro, S. Shioda, R. Horai, M. Asano, K. Sekikawa, Y. Iwakura, S. Numazawa, and T. Yoshida INVOLVEMENT OF INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR {alpha} IN CYP3A11 AND 2C29 DOWN-REGULATION BY BACILLUS CALMETTE-GUERIN AND LIPOPOLYSACCHARIDE IN MOUSE LIVER Drug Metab. Dispos., July 1, 2004; 32(7): 707 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiroi, H. Goto, K. Someya, M. Yanagita, M. Honda, N. Yamanaka, and H. Kiyono HIV Mucosal Vaccine: Nasal Immunization with rBCG-V3J1 Induces a Long Term V3J1 Peptide-Specific Neutralizing Immunity in Th1- and Th2-Deficient Conditions J. Immunol., November 15, 2001; 167(10): 5862 - 5867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Wigginton and D. Kirschner A Model to Predict Cell-Mediated Immune Regulatory Mechanisms During Human Infection with Mycobacterium tuberculosis J. Immunol., February 1, 2001; 166(3): 1951 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. YAMADA, N. SHIJUBO, K. SHIGEHARA, H. OKAMURA, M. KURIMOTO, and S. ABE Increased Levels of Circulating Interleukin-18 in Patients with Advanced Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1786 - 1789. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
